Proceedings: Pharmacological studies with LL 21-945, a new beta-adrenoceptor blocking agent with a long duration of action.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D016275:Atrial Function; D002082:Butylamines / Q000494:pharmacology*; D002415:Cats; D004285:Dogs; D004558:Electric Stimulation; D004987:Ethers / Q000494:pharmacology; D005449:Fluorenes / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006325:Heart Atria / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D010869:Pindolol / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012032:Refractory Period, Electrophysiological / Q000187:drug effects; D013268:Stimulation, Chemical; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D002082:Butylamines; D004987:Ethers; D005449:Fluorenes; D011433:Propranolol; D010869:Pindolol; D007545:Isoproterenol